OCULAR THERAPEUTIX, INC Research and Development Expense
OCULAR THERAPEUTIX, INC (OCUL) reported Research and Development Expense of $54.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC research and development expense for the quarter ending 2026-06-30 was $54.14M, a 5.98% increase year-over-year.
- OCULAR THERAPEUTIX, INC research and development expense for the quarter ending 2026-03-31 was $66.21M, a 54.50% increase year-over-year.
- OCULAR THERAPEUTIX, INC research and development expense for the quarter ending 2025-12-31 was $50.80M, a 23.94% increase year-over-year.
- OCULAR THERAPEUTIX, INC research and development expense for the quarter ending 2025-09-30 was $52.36M, a 41.30% increase year-over-year.
- OCULAR THERAPEUTIX, INC research and development expense for fiscal 2025 was $197.10M, a 54.42% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC research and development expense for fiscal 2024 was $127.64M, a 109.05% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC research and development expense for fiscal 2023 was $61.05M, a 14.20% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC research and development expense for fiscal 2022 was $53.46M, a 6.75% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $54.14M 10-Q · filed 2026-08-03 | $120.35M 10-Q · filed 2026-08-03 | $171.15M derived: sum of 3 quarters · filed 2026-08-03 | $223.51M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $66.21M 10-Q · filed 2026-05-05 | $117.01M derived: sum of 2 quarters · filed 2026-05-05 | $169.37M derived: sum of 3 quarters · filed 2026-05-05 | $220.45M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $50.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $103.16M derived: sum of 2 quarters · filed 2026-02-05 | $154.24M derived: sum of 3 quarters · filed 2026-08-03 | $197.10M 10-K · filed 2026-02-05 |
| 2025-09-30 | $52.36M 10-Q · filed 2025-11-04 | $103.44M derived: sum of 2 quarters · filed 2026-08-03 | $146.30M 10-Q · filed 2025-11-04 | $187.28M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $51.08M 10-Q · filed 2026-08-03 | $93.94M 10-Q · filed 2026-08-03 | $134.93M derived: sum of 3 quarters · filed 2026-08-03 | $171.98M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $42.86M 10-Q · filed 2026-05-05 | $83.85M derived: sum of 2 quarters · filed 2026-05-05 | $120.90M derived: sum of 3 quarters · filed 2026-05-05 | $149.76M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $40.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $78.04M derived: sum of 2 quarters · filed 2026-02-05 | $106.90M derived: sum of 3 quarters · filed 2026-02-05 | $127.64M 10-K · filed 2026-02-05 |
| 2024-09-30 | $37.05M 10-Q · filed 2025-11-04 | $65.91M derived: sum of 2 quarters · filed 2025-11-04 | $86.65M 10-Q · filed 2025-11-04 | $102.84M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-06-30 | $28.86M 10-Q · filed 2025-08-05 | $49.59M 10-Q · filed 2025-08-05 | $65.79M derived: sum of 3 quarters · filed 2026-02-05 | $80.81M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-03-31 | $20.73M 10-Q · filed 2025-05-05 | $36.93M derived: sum of 2 quarters · filed 2026-02-05 | $51.95M derived: sum of 3 quarters · filed 2026-02-05 | $67.04M derived: sum of 4 quarters · filed 2026-02-05 |
| 2023-12-31 | $16.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $31.21M derived: sum of 2 quarters · filed 2026-02-05 | $46.31M derived: sum of 3 quarters · filed 2026-02-05 | $61.05M 10-K · filed 2026-02-05 |
| 2023-09-30 | $15.02M 10-Q · filed 2024-11-14 | $30.11M derived: sum of 2 quarters · filed 2024-11-14 | $44.86M 10-Q · filed 2024-11-14 | $58.40M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $15.09M 10-Q · filed 2024-08-07 | $29.84M 10-Q · filed 2024-08-07 | $43.38M derived: sum of 3 quarters · filed 2025-03-03 | $57.10M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $14.75M 10-Q · filed 2024-05-07 | $28.29M derived: sum of 2 quarters · filed 2025-03-03 | $42.01M derived: sum of 3 quarters · filed 2025-03-03 | $55.11M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $13.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $27.26M derived: sum of 2 quarters · filed 2025-03-03 | $40.36M derived: sum of 3 quarters · filed 2025-03-03 | $53.46M 10-K · filed 2025-03-03 |
| 2022-09-30 | $13.72M 10-Q · filed 2023-11-07 | $26.82M derived: sum of 2 quarters · filed 2023-11-07 | $39.92M 10-Q · filed 2023-11-07 | $52.50M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | $13.10M 10-Q · filed 2023-08-07 | $26.20M 10-Q · filed 2023-08-07 | $38.78M derived: sum of 3 quarters · filed 2024-03-11 | $51.50M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | $13.10M 10-Q · filed 2023-05-08 | $25.68M derived: sum of 2 quarters · filed 2024-03-11 | $38.40M derived: sum of 3 quarters · filed 2024-03-11 | $52.26M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | $12.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $25.30M derived: sum of 2 quarters · filed 2024-03-11 | $39.16M derived: sum of 3 quarters · filed 2024-03-11 | $50.08M 10-K · filed 2024-03-11 |
| 2021-09-30 | $12.72M 10-Q · filed 2022-11-07 | $26.58M derived: sum of 2 quarters · filed 2022-11-07 | $37.51M 10-Q · filed 2022-11-07 | $45.13M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $13.86M 10-Q · filed 2022-08-08 | $24.79M 10-Q · filed 2022-08-08 | $32.41M derived: sum of 3 quarters · filed 2023-03-06 | $39.36M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $10.93M 10-Q · filed 2022-05-09 | $18.55M derived: sum of 2 quarters · filed 2023-03-06 | $25.50M derived: sum of 3 quarters · filed 2023-03-06 | $33.52M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $14.57M derived: sum of 2 quarters · filed 2023-03-06 | $22.60M derived: sum of 3 quarters · filed 2023-03-06 | $28.69M 10-K · filed 2023-03-06 |
| 2020-09-30 | $6.95M 10-Q · filed 2021-11-08 | $14.97M derived: sum of 2 quarters · filed 2021-11-08 | $21.07M 10-Q · filed 2021-11-08 | $31.20M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $8.02M 10-Q · filed 2021-08-09 | $14.12M 10-Q · filed 2021-08-09 | $24.24M derived: sum of 3 quarters · filed 2022-02-28 | $34.48M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $6.10M 10-Q · filed 2021-05-05 | $16.22M derived: sum of 2 quarters · filed 2022-02-28 | $26.46M derived: sum of 3 quarters · filed 2022-02-28 | $35.87M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $10.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $20.36M derived: sum of 2 quarters · filed 2022-02-28 | $29.77M derived: sum of 3 quarters · filed 2022-02-28 | $41.09M 10-K · filed 2022-02-28 |
| 2019-09-30 | $10.23M 10-Q · filed 2020-11-05 | $19.65M derived: sum of 2 quarters · filed 2020-11-05 | $30.97M 10-Q · filed 2020-11-05 | $41.22M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $9.41M 10-Q · filed 2020-08-07 | $20.73M 10-Q · filed 2020-08-07 | $30.99M derived: sum of 3 quarters · filed 2020-08-07 | $40.67M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $11.32M 10-Q · filed 2020-05-08 | $21.57M derived: sum of 2 quarters · filed 2020-05-08 | $31.26M derived: sum of 3 quarters · filed 2020-05-08 | $40.01M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $10.26M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $19.94M derived: sum of 2 quarters · filed 2020-03-12 | $28.69M derived: sum of 3 quarters · filed 2020-03-12 | $36.91M 10-K · filed 2020-03-12 |
| 2018-09-30 | $9.69M 10-Q · filed 2019-11-12 | $18.43M derived: sum of 2 quarters · filed 2019-11-12 | $26.66M 10-Q · filed 2019-11-12 | $34.56M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $8.74M 10-Q · filed 2019-08-07 | $16.97M 10-Q · filed 2019-08-07 | $24.88M derived: sum of 3 quarters · filed 2020-03-12 | $33.01M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $8.23M 10-Q · filed 2019-05-10 | $16.14M derived: sum of 2 quarters · filed 2020-03-12 | $24.26M derived: sum of 3 quarters · filed 2020-03-12 | $32.38M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $7.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $16.03M derived: sum of 2 quarters · filed 2020-03-12 | $24.15M derived: sum of 3 quarters · filed 2020-03-12 | $30.88M 10-K · filed 2020-03-12 |
| 2017-09-30 | $8.13M 10-Q · filed 2018-11-07 | $16.24M derived: sum of 2 quarters · filed 2018-11-07 | $22.97M 10-Q · filed 2018-11-07 | $30.30M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $8.12M 10-Q · filed 2018-08-07 | $14.85M 10-Q · filed 2018-08-07 | $22.17M derived: sum of 3 quarters · filed 2019-03-07 | $27.86M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $6.73M 10-Q · filed 2018-05-08 | $14.06M derived: sum of 2 quarters · filed 2019-03-07 | $19.74M derived: sum of 3 quarters · filed 2019-03-07 | $26.72M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $7.33M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $13.01M derived: sum of 2 quarters · filed 2019-03-07 | $19.99M derived: sum of 3 quarters · filed 2019-03-07 | $27.07M 10-K · filed 2019-03-07 |
| 2016-09-30 | $5.69M 10-Q · filed 2017-11-07 | $12.66M derived: sum of 2 quarters · filed 2017-11-07 | $19.74M 10-Q · filed 2017-11-07 | $26.62M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $6.98M 10-Q · filed 2016-08-09 | $14.05M 10-Q · filed 2017-08-08 | $20.94M derived: sum of 3 quarters · filed 2018-03-08 | $29.20M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $7.07M 10-Q · filed 2017-05-05 | $13.96M derived: sum of 2 quarters · filed 2018-03-08 | $22.22M derived: sum of 3 quarters · filed 2018-03-08 | $28.96M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $6.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $15.15M derived: sum of 2 quarters · filed 2018-03-08 | $21.89M derived: sum of 3 quarters · filed 2018-03-08 | $26.61M 10-K · filed 2018-03-08 |
| 2015-09-30 | $8.26M 10-Q · filed 2016-11-09 | $15.01M derived: sum of 2 quarters · filed 2016-11-09 | $19.73M 10-Q · filed 2016-11-09 | $24.87M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $6.74M 10-Q · filed 2016-08-09 | $11.46M 10-Q · filed 2016-08-09 | $16.61M derived: sum of 3 quarters · filed 2017-03-10 | $21.09M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $4.72M 10-Q · filed 2016-05-10 | $9.87M derived: sum of 2 quarters · filed 2017-03-10 | $14.35M derived: sum of 3 quarters · filed 2017-03-10 | $18.64M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | $5.15M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $9.63M derived: sum of 2 quarters · filed 2017-03-10 | $13.92M derived: sum of 3 quarters · filed 2017-03-10 | $18.88M 10-K · filed 2017-03-10 |
| 2014-09-30 | $4.48M 10-Q · filed 2015-11-10 | $8.77M derived: sum of 2 quarters · filed 2015-11-10 | $13.73M 10-Q · filed 2015-11-10 | $16.57M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | $4.29M 10-Q · filed 2015-08-10 | $9.25M 10-Q · filed 2015-08-10 | $12.09M derived: sum of 3 quarters · filed 2016-03-10 | $14.88M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | $4.96M 10-Q · filed 2015-05-15 | $7.80M derived: sum of 2 quarters · filed 2016-03-10 | $10.58M derived: sum of 3 quarters · filed 2016-03-10 | $12.99M derived: sum of 4 quarters · filed 2016-03-10 |
| 2013-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $5.63M derived: sum of 2 quarters · filed 2016-03-10 | $8.03M derived: sum of 3 quarters · filed 2016-03-10 | $10.52M 10-K · filed 2016-03-10 |
| 2013-09-30 | $2.78M 10-Q · filed 2014-11-12 | $5.19M derived: sum of 2 quarters · filed 2014-11-12 | $7.67M 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $2.40M 10-Q · filed 2014-08-29 | $4.89M 10-Q · filed 2014-08-29 | ||
| 2012-12-31 | $11.54M 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |